Ribas Antoni, Hu-Lieskovan Siwen
Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles (UCLA), Los Angeles, CA 90095
Jonsson Comprehensive Cancer Center (JCCC), University of California, Los Angeles (UCLA), Los Angeles, CA 90095.
J Exp Med. 2016 Dec 12;213(13):2835-2840. doi: 10.1084/jem.20161462. Epub 2016 Nov 30.
Expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) is used to select patients and analyze responses to anti-PD-1/L1 antibodies. The expression of PD-L1 is regulated in different ways, which leads to a different significance of its presence or absence. PD-L1 positivity may be a result of genetic events leading to constitutive PD-L1 expression on cancer cells or inducible PD-L1 expression on cancer cells and noncancer cells in response to a T cell infiltrate. A tumor may be PD-L1 negative because it has no T cell infiltrate, which may be reversed with an immune response. Finally, a tumor that is unable to express PD-L1 because of a genetic event will always be negative for PD-L1 on cancer cells.
程序性死亡蛋白1(PD-1)配体1(PD-L1)的表达用于选择患者并分析对抗PD-1/L1抗体的反应。PD-L1的表达受到不同方式的调控,这导致其存在或不存在具有不同的意义。PD-L1阳性可能是遗传事件导致癌细胞上组成性PD-L1表达的结果,或者是癌细胞和非癌细胞在T细胞浸润的反应中诱导性PD-L1表达的结果。肿瘤可能是PD-L1阴性,因为它没有T细胞浸润,这可能会因免疫反应而逆转。最后,由于遗传事件而无法表达PD-L1的肿瘤在癌细胞上的PD-L1将始终为阴性。